Federal Circuit Confirms Patentability Of Epilepsy Treatment
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Feb. 1 rejected a challenge to an adverse inter partes review (IPR) by the Patent Trial and Appeal Board, agreeing...To view the full article, register now.
Already a subscriber? Click here to view full article